PMID- 29063951
OWN - NLM
STAT- MEDLINE
DCOM- 20190417
LR  - 20190417
IS  - 1432-1963 (Electronic)
IS  - 0172-8113 (Linking)
VI  - 38
IP  - Suppl 2
DP  - 2017 Nov
TI  - [Biliary tract cancers : Molecular characterization and identification of novel 
      prognostic markers].
PG  - 192-197
LID - 10.1007/s00292-017-0359-9 [doi]
AB  - BACKGROUND: Bile duct cancers (BTCs) are highly aggressive tumors with a dismal 
      prognosis and an increasing incidence. BTC is a tumorbiologically and clinically 
      heterogeneous tumor group and can be subdivided according to anatomical aspects 
      into intrahepatic cholangiocarcinomas (iCCA), extrahepatic cholangiocarcinomas 
      (eCCA) and gallbladder carcinomas (GBC). NEW THERAPY OPTIONS: Chronic 
      inflammatory processes of the biliary system seem to play a role in the 
      development of these tumors. Insights into molecular cholangiocarcinogenesis 
      could make an important contribution to novel and more precise classification 
      attempts and to the development of new, targeted therapies for BTC. EPIGENETIC 
      AND GENETIC ALTERATIONS IN CHOLANGIOCARCINOMAS: The first description of 
      genome-wide DNA methylation patterns in CCA showed drastic global methylation 
      differences between CCA and corresponding non-neoplastic tissue (matched-pair 
      analyses). Moreover, significant methylation differences between the CCA subtypes 
      (eCCA and iCCA) could be found. Using immunohistochemistry and Sanger sequencing, 
      it was shown that the actual BRAF V600E mutation rate seems to be significantly 
      lower (1.3%) than previously described in the literature. IMMUNEPHENOTYPING IN 
      BILIARY TRACT CANCERS: A comprehensive, subtype-specific characterization of 
      tumor-infiltrating immune cells as well as an expression analysis of Major 
      Histocompatibility Complex I was performed in a large and well-characterized BTC 
      cohort. For further studies on the efficacy of immunomodulatory therapy 
      approaches for BTC, the presented results provide a solid basis.
FAU - Goeppert, B
AU  - Goeppert B
AD  - Pathologisches Institut, Universitatsklinikum Heidelberg, Im Neuenheimer 
      Feld 224, 69120, Heidelberg, Deutschland. benjamin.goeppert@uni-heidelberg.de.
LA  - ger
PT  - Journal Article
PT  - Review
TT  - Karzinome der Gallenwege : Molekulare Charakterisierung und Identifikation neuer 
      prognostischer Marker.
PL  - Germany
TA  - Pathologe
JT  - Der Pathologe
JID - 8006541
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Biliary Tract Neoplasms/*pathology/therapy
MH  - *Biomarkers, Tumor
MH  - Humans
MH  - Prognosis
OTO - NOTNLM
OT  - Bile duct cancer
OT  - Carcinogenesis
OT  - Cholangiocarcinoma
OT  - Gallbladder
OT  - Liver neoplasms
EDAT- 2017/10/25 06:00
MHDA- 2019/04/18 06:00
CRDT- 2017/10/25 06:00
PHST- 2017/10/25 06:00 [pubmed]
PHST- 2019/04/18 06:00 [medline]
PHST- 2017/10/25 06:00 [entrez]
AID - 10.1007/s00292-017-0359-9 [pii]
AID - 10.1007/s00292-017-0359-9 [doi]
PST - ppublish
SO  - Pathologe. 2017 Nov;38(Suppl 2):192-197. doi: 10.1007/s00292-017-0359-9.